Fortitude Family Office LLC Has $341,000 Holdings in Pfizer Inc. (NYSE:PFE)

Fortitude Family Office LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,859 shares of the biopharmaceutical company’s stock after selling 904 shares during the period. Fortitude Family Office LLC’s holdings in Pfizer were worth $341,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Strategic Financial Concepts LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at $38,000. Quest Partners LLC purchased a new stake in shares of Pfizer during the second quarter worth $570,000. Angeles Wealth Management LLC boosted its position in Pfizer by 24.0% during the second quarter. Angeles Wealth Management LLC now owns 11,580 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 2,239 shares during the last quarter. AGF Management Ltd. grew its stake in Pfizer by 6.7% in the second quarter. AGF Management Ltd. now owns 1,223,841 shares of the biopharmaceutical company’s stock valued at $34,243,000 after purchasing an additional 76,464 shares in the last quarter. Finally, HHM Wealth Advisors LLC increased its position in Pfizer by 9.3% in the 2nd quarter. HHM Wealth Advisors LLC now owns 6,311 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 538 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Price Performance

NYSE PFE opened at $26.92 on Friday. The stock has a 50-day simple moving average of $26.21 and a 200 day simple moving average of $28.05. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market capitalization of $152.56 billion, a PE ratio of 36.38, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.39%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.